CAGE Bio’s CGB-500 Shows Best-in-Class Results in Atopic Dermatitis Phase 2b Trial

CAGE Bio has announced positive topline results from its Phase 2b, double-blinded, dose-ranging trial of CGB-500, an investigational topical drug for atopic dermatitis (AD).

The study met primary and secondary endpoints, demonstrating best-in-class efficacy, rapid itch relief, and a strong safety profile.

Key Phase 2b Results

• Patient population: 180 patients ≥12 years old, across 16 US sites.
• Disease severity: 85% moderate, 9% mild, 6% severe. All had <10% affected body surface area (BSA).
• Efficacy outcomes:
  - 59% achieved Investigator’s Global Assessment (IGA) treatment success (Clear or Almost Clear, ≥2-grade improvement).
  - 71% experienced a ≥4-point improvement in worst itch (PP-NRS).
  - 35% achieved complete itch resolution (0 itch score).
• Benchmarking: Outcomes exceeded reported results for other topical AD therapies.
• Safety: Well tolerated with no new or unexpected safety signals.

Expert Commentary

Dr. Justin Ko, Board-Certified Dermatologist and SAB Chair, CAGE Bio:

“Patients with moderate-to-severe AD and low BSA involvement have limited topical options. CGB-500 may provide a safe, localized alternative to systemic drugs. Rapid itch relief and strong disease clearance rates make this highly attractive.”

Dr. Samir Mitragotri, Inventor of the Ionic Liquid Platform:

“Ionic liquid technology enables local drug delivery with systemic-like efficacy but a topical safety profile. This advantage is now translating into clear patient benefit.”

Dr. Nitin Joshi, CEO, CAGE Bio:

“These results mark an important milestone for CAGE Bio and patients with AD. We are moving quickly toward Phase 3 trials and potential registration.”

Why It Matters

• High unmet need: In the US, 6.6 million people suffer from moderate-to-severe AD, most with <10% BSA involvement. Current topical therapies often fall short, and systemic drugs are frequently prescribed despite localized disease.
• Potential shift in treatment: CGB-500 could become a topical, high-efficacy alternative for this underserved patient population.

Next Steps

• Full data will be presented at an upcoming scientific congress.
• Phase 3 development planned to advance rapidly.

About CAGE Bio

CAGE Bio is a biotechnology company developing ionic liquid–based therapies for immune-mediated skin diseases. Its pipeline includes clinical and preclinical assets targeting high-incidence dermatological conditions.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!